๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Rapid throughput screening of apparent KSP values for weakly basic drugs using 96-well format

โœ Scribed by Jeremy Guo; Paul. A. Elzinga; Michael. J. Hageman; James N. Herron


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
159 KB
Volume
97
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

โœฆ Synopsis


A rapid-throughput screening assay was developed to estimate the salt solubility parameter, K(SP), with a minimal quantity of drug. This assay allows for early evaluation of salt limited solubility with a large number of counter-ions and biologically promising drug leads. Drugs dissolved (typically 10 mM) in DMSO are robotically distributed to a 96-well plate. DMSO is evaporated, and drugs are equilibrated with various acids at different concentrations (typically <1 M) to yield final total drug concentrations around 2.5 mM. The plate is checked for precipitation. Filtrates from only those precipitated wells were subjected to rapid gradient HPLC analysis. An iterative procedure is employed to calculate all species concentrations based on mass and charge balance equations. The apparent K(SP) values assuming 1:1 stoichiometry are determined from counter-ion and ionized drug activities. A correlation coefficient >0.975 for eight drugs totaling 16 salts is reported. Intra-day and inter-day reproducibility was <10%. Conventional apparent K(SP) measurements were translated to 96-well format for increased throughput and minimal drug consumption (typically 10 mg) to evaluate at least eight different counter-ions. Although the current protocol estimates K(SP) from 10(-3) to 10(-7) M, the dynamic range of the assay could be expanded by adjusting drug and counter-ion concentrations.


๐Ÿ“œ SIMILAR VOLUMES


Rapid throughput solubility screening me
โœ Jeremy Guo; Paul A. Elzinga; Michael. J. Hageman; James N. Herron ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 303 KB

A rapid solubility-screening assay was developed with a focus on Biopharmaceutic Classification Scheme (BCS) class II drug solubility in animal and simulated human gastrointestinal (GI) fluids. The assay enables biologically promising drug leads to be evaluated for solubility limitations earlier in